tbuckley/cabot-search huggingface dataset:
e-Cigarette Use Among Youth in the United States, 2019
Authors: Karen A. Cullen, Andrea S. Gentzke, Michael D. Sawdey, Joanne T. Chang, Gabriella M. Anic, Teresa W. Wang, MeLisa R. Creamer, Ahmed Jamal, Bridget K. Ambrose, Brian A. King
Journal: JAMA (2019)

The prevalence of e-cigarette use among US youth increased from 2011 to 2018. Continued monitoring of the prevalence of e-cigarette and other tobacco product use among youth is important to inform public health policy, planning, and regulatory efforts.To estimate the prevalence of e-cigarette use among US high school and middle school students in 2019 including frequency of use, brands used, and use of flavored products.Cross-sectional analyses of a school-based nationally representative sample of 19 018 US students in grades 6 to 12 participating in the 2019 National Youth Tobacco Survey. The survey was conducted from February 15, 2019, to May 24, 2019.Self-reported current (past 30-day) e-cigarette use estimates among high school and middle school students; frequent use (≥20 days in the past 30 days) and usual e-cigarette brand among current e-cigarette users; and use of flavored e-cigarettes and flavor types among current exclusive e-cigarette users (no use of other tobacco products) by school level and usual brand. Prevalence estimates were weighted to account for the complex sampling design.The survey included 10 097 high school students (mean [SD] age, 16.1 [3.0] years; 47.5% female) and 8837 middle school students (mean [SD] age, 12.7 [2.8] years; 48.7% female). The response rate was 66.3%. An estimated 27.5% (95% CI, 25.3%-29.7%) of high school students and 10.5% (95% CI, 9.4%-11.8%) of middle school students reported current e-cigarette use. Among current e-cigarette users, an estimated 34.2% (95% CI, 31.2%-37.3%) of high school students and 18.0% (95% CI, 15.2%-21.2%) of middle school students reported frequent use, and an estimated 63.6% (95% CI, 59.3%-67.8%) of high school students and 65.4% (95% CI, 60.6%-69.9%) of middle school students reported exclusive use of e-cigarettes. Among current e-cigarette users, an estimated 59.1% (95% CI, 54.8%-63.2%) of high school students and 54.1% (95% CI, 49.1%-59.0%) of middle school students reported JUUL as their usual e-cigarette brand in the past 30 days; among current e-cigarette users, 13.8% (95% CI, 12.0%-15.9%) of high school students and 16.8% (95% CI, 13.6%-20.7%) of middle school students reported not having a usual e-cigarette brand. Among current exclusive e-cigarette users, an estimated 72.2% (95% CI, 69.1%-75.1%) of high school students and 59.2% (95% CI, 54.8%-63.4%) of middle school students used flavored e-cigarettes, with fruit, menthol or mint, and candy, desserts, or other sweets being the most commonly reported flavors.In 2019, the prevalence of self-reported e-cigarette use was high among high school and middle school students, with many current e-cigarette users reporting frequent use and most of the exclusive e-cigarette users reporting use of flavored e-cigarettes.
Allogeneic Hematopoietic Stem Cell Transplantation Following Reduced-Intensity Conditioning Regimen for Elderly Patients (60 years and older) with Hematological Malignancies Using Unrelated Donors: A Retrospective Study on Behalf of the French Society for Stem Cell Transplantation and Cell Therapies (SFGM-TC)
Authors: Jean El Cheikh, Patrick Sfumato, Nathalie Fegueux, Mohamad Mohty, Ibrahim Yakoub-Agha, Stephane Vigouroux, Yves Beguin, Gerard Socie, Jerome Cornillon, Sylvain Thepot, Jacques-Olivier Bay, Mauricette Michallet, Regis Peffault de Latour
Journal: Blood (2014)
Expression of the Tigit/CD226/CD155 Receptors/Ligand System in Chronic Lymphocytic Leukemia
Authors: Francesca Arruga, Giulia Guerra, Denis Baev, Catherine Hoofd, Marta Coscia, Giovanni Francesco D'Arena, Gianluca Gaidano, Richard R. Furman, Silvia Deaglio
Journal: Blood (2019)
Megakaryopoiesis and Platelet-Innate Immune Cell Interactions Are Developmentally Regulated
Authors: Kathleen E. McGrath, Catherman C Seana, Zachary T Hilt, Katherine H Fegan, Paul D. Kingsley, Leah A Vitt, Massiel Chavez Stolla, Craig N. Morrell, James Palis
Journal: Blood (2019)
Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation
Authors: Marco V. Perez, Kenneth W. Mahaffey, Haley Hedlin, John S. Rumsfeld, Ariadna Garcia, Todd Ferris, Vidhya Balasubramanian, Andrea M. Russo, Amol Rajmane, Lauren Cheung, Grace Hung, Justin Lee, Peter Kowey, Nisha Talati, Divya Nag, Santosh E. Gummidipundi, Alexis Beatty, Mellanie True Hills, Sumbul Desai, Christopher B. Granger, Manisha Desai, Mintu P. Turakhia
Journal: New England Journal of Medicine (2019)

Optical sensors on wearable devices can detect irregular pulses. The ability of a smartwatch application (app) to identify atrial fibrillation during typical use is unknown.Participants without atrial fibrillation (as reported by the participants themselves) used a smartphone (Apple iPhone) app to consent to monitoring. If a smartwatch-based irregular pulse notification algorithm identified possible atrial fibrillation, a telemedicine visit was initiated and an electrocardiography (ECG) patch was mailed to the participant, to be worn for up to 7 days. Surveys were administered 90 days after notification of the irregular pulse and at the end of the study. The main objectives were to estimate the proportion of notified participants with atrial fibrillation shown on an ECG patch and the positive predictive value of irregular pulse intervals with a targeted confidence interval width of 0.10.We recruited 419,297 participants over 8 months. Over a median of 117 days of monitoring, 2161 participants (0.52%) received notifications of irregular pulse. Among the 450 participants who returned ECG patches containing data that could be analyzed - which had been applied, on average, 13 days after notification - atrial fibrillation was present in 34% (97.5% confidence interval [CI], 29 to 39) overall and in 35% (97.5% CI, 27 to 43) of participants 65 years of age or older. Among participants who were notified of an irregular pulse, the positive predictive value was 0.84 (95% CI, 0.76 to 0.92) for observing atrial fibrillation on the ECG simultaneously with a subsequent irregular pulse notification and 0.71 (97.5% CI, 0.69 to 0.74) for observing atrial fibrillation on the ECG simultaneously with a subsequent irregular tachogram. Of 1376 notified participants who returned a 90-day survey, 57% contacted health care providers outside the study. There were no reports of serious app-related adverse events.The probability of receiving an irregular pulse notification was low. Among participants who received notification of an irregular pulse, 34% had atrial fibrillation on subsequent ECG patch readings and 84% of notifications were concordant with atrial fibrillation. This siteless (no on-site visits were required for the participants), pragmatic study design provides a foundation for large-scale pragmatic studies in which outcomes or adherence can be reliably assessed with user-owned devices. (Funded by Apple; Apple Heart Study ClinicalTrials.gov number, NCT03335800.).
“Touchy-feely” psychiatrist is suspended for six months
Authors: Clare Dyer
Journal: BMJ (2019)

A psychiatrist whose “touchy-feely” advances led five female colleagues to complain about him has been suspended from the UK medical register for six months.

James Ugbo’s “unwelcome, flirtatious comments and unnecessary and unwanted physical contact” over a two year period from 2015 to 2017 at Elmleigh psychiatric hospital near Portsmouth had breached his female colleagues’ trust, said Rob Ward, chairing the medical practitioners tribunal.

“The tribunal found that this …
Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models
Authors: Qi Zhang, Sajid Khan, Xuan Zhang, Vinitha Mary Kuruvilla, Sanaz Ghotbaldini, Julia Wells, Natalia Baran, Tianyu Cai, Lina Han, Adolfo Ferrando, Yong-Mi Kim, Guangrong Zheng, Daohong Zhou, Marina Y Konopleva
Journal: Blood (2019)
The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation
Authors: Arnon Nagler, Bhagirathbhai Dholaria, Myriam Labopin, Gerard Socie, Anne Huynh, Maija Itälä-Remes, Eric Deconinck, Ibrahim Yakoub-Agha, Jean-Yves Cahn, Jean-Henri Bourhis, Hélène Labussière-Wallet, Sylvain Chantepie, Jordi Esteve, Bipin Savani, Mohamad Mohty
Journal: Leukemia (2019)
Low Lymphocyte Count at Day 30 after Single Cord Blood Transplantation Had Negative Impact on Survival, Because of Higher NRM Rate
Authors: Mitsuhiro Yuasa, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Shinsuke Takagi, Hisashi Yamamoto, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Akiko Yoneyama, Shigeyoshi Makino, Naoyuki Uchida, Shuichi Taniguchi
Journal: Blood (2019)
Cdx Report Program: Heterogeneity Revealed in Current Reporting Practices for Hemato-Oncology Companion Diagnostic (CDx) Markers in Multiple Countries
Authors: Sabit Delic, Piers Blombery, María José Calasanz, Devon S. Chabot-Richards, Dolors Colomer, Matteo G Della Porta, Paul A S Evans, Torsten Haferlach, Joanne Mason, Jay L Patel, William S. Stevenson, Christian Thiede, Maria Teresa Voso, Jordan Clark
Journal: Blood (2019)
RARE-45. ACTIVITY OF LAROTRECTINIB IN TRK FUSION CANCER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMORS
Authors: Francois Doz, Birgit Geoerger, Steven G DuBois, Juneko E Grilley-Olson, Cornelis M van Tilburg, Antoine Italiano, Andrej Lissat, Hyoung Jin Kang, Makoto Tahara, Valentina Boni, Sebastien Perreault, Michael Capra, Shivani Nanda, Nicoletta Brega, Ariadna Holynskyj, David S Ziegler, David S Hong, David M Hyman, Alexander Drilon
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND TRK fusions are oncogenic drivers of a variety of tumors, many of which can involve the central nervous system (CNS). Larotrectinib is a selective TRK inhibitor FDA-approved for the treatment of TRK fusion cancers (Drilon et al., NEJM 2018). Here we report on the clinical activity of larotrectinib in an expanded set of TRK fusion-positive primary CNS tumors. METHODS Patients with primary CNS tumors harboring a TRK fusion treated with larotrectinib on two clinical trials (NCT02637687 and NCT02576431) were identified by local molecular testing. Larotrectinib was administered until disease progression, withdrawal, or unacceptable toxicity. Disease status was investigator assessed (RANO). Data cutoff: February 19, 2019. RESULTS 18 patients with various histological types of glial tumors (11 high-grade, 4 low-grade, 3 unknown) were identified. The patients had gene fusions involving NTRK2 (n=13), NTRK1 (n=2) and NTRK3 (n=2); one was not determined. Median age was 10 years (range 1–79); 14 patients were pediatric (&lt; 18). In 14 evaluable patients, the objective response rate was 36% (2 CR, 3 PR), with responses seen in high- and low-grade disease and across histologies. Nine patients had SD. The 24-week disease control rate was 71%. The duration of treatment ranged from 0.03+ to 16.6+ months. One patient (3.7 years old) with glioblastoma progressed after 5.5 months on larotrectinib. Sequencing revealed a solvent front mutation and the patient was subsequently enrolled in compassionate use protocol for BAY2731954 (formerly known as LOXO-195). CONCLUSION Larotrectinib is active in patients with TRK fusion cancer with intracranial disease. Confirmed responses and durable disease control were seen in primary CNS tumors of various grades and histologies. These results further support expanded testing for NTRK gene fusions in patients with primary CNS tumors.
Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)
Authors: Xiaoyi Wang, Rong Wang, Chi Zhang, Amer M. Zeidan, Nikolai A. Podoltsev, Scott F. Huntington, Steven D. Gore, Amy J Davidoff, Xiaomei Ma
Journal: Blood (2019)
ANGI-06. FUNCTION OF FORMIN-LIKE 1 (FMNL1) IN GLIOBLASTOMA MULTIFORME
Authors: Nayuta Higa, Yoshinari Shinsato, Tomoko Takajyo, Hajime Yonezawa, Hiroyuki Uchida, Tatsuhiko Furukawa, Koji Yoshimoto
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Glioblastoma multiforme is the most common primary malignant brain tumour in adults. It is characterised by rapid proliferation, aggressive migration, and invasion into normal brain tissue. Formin proteins have been implicated in cancer progression, invasion, and migration. However, the role of FMNL1 in cancer remains unclear. We are the first to investigate FMNL1 in GBM. METHODS Clinical specimens were obtained from tumours surgically removed and pathologically confirmed as GBM from 217 GBM patients treated from 2000 to 2015 at the Department of Neurosurgery, Kagoshima University Hospital. We studied the expression of FMNL1 in glioblastoma samples by immunohistochemistry to analyse the correlation between FMNL1 expression, clinicopathologic variables, and patient survival. Migration and invasion assays were used to verify the effect of FMNL1 on glioblastoma cell lines. Microarray data were downloaded from TCGA and analysed using Gene Set Enrichment Analysis (GSEA). RESULTS FMNL1 was found to be a predictor of poor prognosis in a cohort of 217 cases (P &lt; 0.001). GSEA showed that upregulation and downregulation of FMNL1 were associated with mesenchymal and proneural markers, respectively. Contrarily, downregulation of FMNL1 suppressed migration and invasion of glioblastoma multiforme cells via DIAPH1 and GOLGA2, respectively. Downregulation of FMNL1 also suppressed assembly of actin fibres, induced morphological changes, and diminished filamentous actin. CONCLUSION Our studies show that abundant FMNL1 expression in GBM patients is correlated with an unfavourable prognosis. FMNL1 is a promising therapeutic target and a useful biomarker for GBM progression.
RBTT-09. A PHASE 1 STUDY OF CEMIPLIMAB IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY (R/R) SOLID AND CENTRAL NERVOUS SYSTEM (CNS) TUMORS
Authors: Cassie Kline, Jonathan D Schoenfeld, Paul J Catalano, Jingjin Li, Anne J Paccaly, Tasha N Sims, Amy-Lee Bredlau, Michael Prados, Daphne Haas-Kogan, Sabine Mueller
Journal: Neuro-Oncology (2019)

Abstract DIPG and HGG lead to the majority of pediatric cancer-related deaths. Despite multimodal treatment, the 2-year survival rates for DIPG and HGG are less than 10% and 20%, respectively. Anti-PD-1 therapy combined with radiotherapy has demonstrated synergistic anti-tumor effects. Cemiplimab, a human PD-1 monoclonal antibody, has demonstrated safety and efficacy in patients with advanced malignancies. Combination of cemiplimab with radiation has the potential to be an effective treatment for pediatric patients with DIPG or HGG. This is a multicenter, Phase 1 and early efficacy study (NCT03690869). Phase 1 will enroll pediatric patients with R/R solid or CNS tumors (N≥30) into two age cohorts (0 to &lt; 12 and 12 to &lt; 18 years). Cemiplimab will be administered intravenously every 2 weeks as monotherapy. Primary objectives of Phase 1 are to confirm safety and assess the pharmacokinetics (PK) of cemiplimab to recommend a Phase 2 dose (RP2D) for clinical efficacy assessment. The Efficacy phase will enroll patients with newly diagnosed DIPG or HGG (dose escalation: N≥12 patients each; dose expansion: N≤40 patients each), or recurrent HGG (dose escalation: N≥6 patients; dose expansion: ≤20 patients) into two age cohorts (≥3 to &lt; 12 years and 12 to ≤25 years). There will be two treatment arms for patients with newly diagnosed DIPG or HGG: cemiplimab in combination with conventionally fractionated (Arm 1) or hypofractionated (Arm 2) radiotherapy. Patients with recurrent HGG will receive cemiplimab concomitantly with reirradiation. All patients will continue cemiplimab as monotherapy at completion of combination therapy. Primary objectives of Efficacy Phase are to confirm safety and anticipated RP2D, assess PK, and determine survival and antitumor activity at 12 months (overall survival for newly diagnosed DIPG and recurrent HGG; progression-free survival for newly diagnosed HGG) of cemiplimab when given concomitantly with radiation. This study is currently recruiting patients across multiple sites.
Encouraging Results with ALL IC-BFM 2009 Protocol Therapy in Pediatric Acute Lymphoblastic Leukemia/Lymphoma in Resource-Limited Setting: A Single-Center Study from India
Authors: Uttam Kumar Nath, Debranjani Chattopadhyay, Anamika Bakliwal, Sudeep Vaniyath, Rituparna Chetia, Ashok K Rajoreya
Journal: Blood (2019)
Development of a Real Time Pharmacokinetic Testing Method to Allow for Targeted Melphalan Dosing in Multiple Myeloma Patients Undergoing Autologous Transplant
Authors: Karen Sweiss, Bhaskar Vemu, Gregory Sampang Calip, John P Galvin, John G. Quigley, Nadim Mahmud, Damiano Rondelli, Jeremy Johnson, Pritesh Patel
Journal: Blood (2019)
Cell Adhesion of ALL to Stromal Cells May Mediate CAR T-Cell Resistance: A Novel Escape Mechanism for Immunotherapy
Authors: Hye Na Kim, Enzi Jiang, Ruan Yongsheng, Heather Ogana, Nour Abdel-Azim, Justin Le, Annie Luong, Halvard Bonig, Nabil Ahmed, Moghimi Babak, Michael A. Pulsipher, Deepa Bhojwani, Alan S. Wayne, Chintan Parekh, Hisham Abdel-Azim, Nora Heisterkamp, Yong-Mi Kim
Journal: Blood (2019)
T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma
Authors: Lekha Mikkilineni, Elisabet E. Manasanch, Norris Lam, Danielle Vanasse, Jennifer N. Brudno, Irina Maric, Jeremy J. Rose, Maryalice Stetler-Stevenson, Hao-Wei Wang, Constance M. Yuan, David F. Stroncek, Jennifer Mann, Micaela Ganadan, Rashmika Patel, Nathan Trinklein, Ben Buelow, Ronald E. Gress, James N. Kochenderfer
Journal: Blood (2019)
NIMG-22. DEVELOPMENT AND VALIDATION OF A RADIOMIC MODEL FOR RWDD3 EXPRESSION PREDICTION IN PATIENTS WITH ACROMEGALY
Authors: Yanghua Fan, Renzhi Wang, Ming Feng
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND The expression of RWDD3 is closely related to the prognosis of acromegaly. Therefore, this study aimed to investigate a radiomics method based on MRI to noninvasively evaluate RWDD3 expression in acromegaly. MATERIAL AND METHODS 132 patients with acromegaly were enrolled and divided into primary (n=88) and validation cohorts (n=44) according. The expression of RWDD3 was determined by immunohistochemistry. Radiomic features were extracted from the MR images and determined using the ‘Elastic Net’ feature selection algorithm. A radiomic signature was built using a support vector machine. Subsequently, multivariable logistic regression analysis was used to select the most informative clinical features, and a radiomic model, incorporating the radiomic signature and selected clinical features, was constructed and used as the final predictive model. The performance of this radiomic model was validated using receiver operating characteristics analysis, and its calibration, discriminating ability, and clinical usefulness were assessed. RESULTS The radiomic signature, which was constructed with radiomic features selected using the primary cohort, showed a favorable discriminatory ability in the validation cohort. The radiomic model incorporating the radiomic signature and three selected clinical features showed good discrimination abilities and calibration, with an area under the curve (AUC) of 0.89 for the primary cohort and 0.84 for the validation cohort. The radiomic model better estimated the treatment responses of patients with acromegaly than did the clinical features. Decision curve analysis showed the radiomic model was clinically useful. CONCLUSION This radiomic model could aid neurosurgeons in the prediction of RWDD3 expression in patients with acromegaly, and could contribute to predicting of patient prognoses.
Infections Associated with CAR T Therapy for Treatment of Hematological Malignancies
Authors: Tariq Iqtidar Sadiq Syed, Syed Maaz Abdullah, Tayyab Rehan, Muhaddis Ejaz Ahmad, Syeda Sabeeka Batool, Muhammad Abdullah Yousaf, Maaz Ahmed Yusufi, Saif Ur Rehman, Sravanthi Kotapati, Maimoona Khan, Asma Waheed, Zainab Ijaz, Awais Ijaz, Faiz Anwer
Journal: Blood (2019)
Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL
Authors: Jae H. Park, Jessica Flynn, Mithat Gonen, Yvette Bernal, Claudia Diamonte, Elizabeth Halton, Xiuyan Wang, Isabelle Riviere, Michel Sadelain, Renier J. Brentjens
Journal: Blood (2019)
GECAT - German Evaluation of Cancer Associated Thrombosis: A Prospective Register Trial for Patients with Active Cancer and Venous Thromboembolism (VTE) in Berlin
Authors: Marianne Sinn, Christiane Pollich, Hanno Riess, Sven Bischoff, Piet Habbel, Christian W Scholz, Ernst Spaeth-Schwalbe, Maike de Wit, Anja Jühling, Eike Wolter, Lilianna Wislocka, Dr. Klamroth
Journal: Blood (2019)
Mesenchymal Stem Cells from Patients with Myelodysplastic Syndromes Are Functionally and Genomically Abnormal.
Authors: Olga López Villar, Fermin M. Sánchez-Guijo, Juan Luis García, Jose Ramon González Porras, Eva Villarón, Natalia López-Holgado, Jose Antonio Pérez Simón, J.F. San Miguel, María Consuelo Del Cañizo
Journal: Blood (2007)
Nicotinamide and Blood Sugar
Authors: J. N. Cumings
Journal: BMJ (1947)

SUPPRESSION OF SYPHILIS AND PRECOCIOUS TERTIARISMMEDBcALTIJ 613 apparently unaltered.Penicillin treatment was purposely de- layed so that non-specific effects could be excluded.Ten days after* beginning treatment, penicillin in oil-wax suspen- sion having been superimposed on the arsenic-bismuth therapy, only scattered pigmentation remained on the face and the gum- matous lesion was obviously healing rapidly. ConclusionsIt seems probable that in November, 1945, this man had secondary syphilis, possibly masked by scabies, and that the small amount of penicillin (about 600,000 units) given at that time was sufficient temporarily to suppress the diFease.The relapse lesions, appearing 18 months later, were of a secondo-tertiary type.This case suggests that penicillin in inadequate dosage over a short period can, like the arsphenamines, produce the phenomenon of precocious tertiarism.It illustrates the importance of making an accurate diagnosis in any dermato- logical condition before using penicillin by injection.